Live tape
Top 8, mentions 7d30,017NVDA14,564 mentions▲ +0.04ANT4,160 mentions▲ +0.06GOOGL2,936 mentions▲ +0.04SPY2,248 mentions▲ +0.05QQQ1,804 mentions▲ +0.04SPCX1,748 mentions▲ +0.08AMD1,367 mentions▲ +0.06AAPL1,190 mentions▲ +0.04

Equity · Healthcare

ALLO

NASDAQ

Allogene Therapeutics (ALLO)

0.6242 USD −5.75% vs prior close Nov 20, 2026
Allogene Therapeutics, Inc. price graph
64 sessions
2.5 0.5 24 Aug 20 Nov

The line runs 2.04 USD on 24 August through 0.6242 USD on 20 November, on a scale from 0.5 to 2.5. Days the market did not trade hold the previous close, flat.

Market cap
216.2M USD
Revenue, year to Dec 2025
0 USD
EPS, diluted, year to Dec 2025
−0.87 USD
Avg volume
417.6K

as of Nov 20, 2026

Have Allogene Therapeutics (ALLO) insiders bought or sold shares recently?

In the 90 days to 22 Nov 2026, Allogene Therapeutics insiders reported 1 open-market sale and no purchases (SEC Form 4); the filings we hold, back to 21 Oct 2025, show no open-market purchase.

Form 4, 90 days to 22 Nov 2026, newest reported trade 21 Oct 2026

0buys
1sells
$49Knet sold
0other filings
Have Allogene Therapeutics (ALLO) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
21 Oct 2026Parker Geoffrey M.CHIEF FINANCIAL OFFICERSell36,34249K USD

Which funds hold Allogene Therapeutics (ALLO)?

9 of the 45 institutional funds we track reported a Allogene Therapeutics position for the quarter ended 30 Sep 2026 — a combined 91.7M USD; the latest of those filings landed 16 Nov 2026.

Form 13F

Which funds hold Allogene Therapeutics (ALLO)?
FundPositionSharesValueShares q/q
Citadel AdvisorsAdded24,558,32539.3M USD+143.4%
Two Sigma InvestmentsHeld (±25%)9,012,67714.4M USD+15.8%
Marshall WaceAdded7,973,64712.8M USD+56.5%
Renaissance TechnologiesAdded5,232,0128.4M USD+36.5%
Millennium ManagementHeld (±25%)5,115,5358.2M USD+5.6%
D. E. Shaw & Co.Held (±25%)4,261,3156.8M USD−9.5%
Man GroupTrimmed518,882830K USD−26.1%
Point72 Asset ManagementNew position368,461590K USD
AQR Capital ManagementTrimmed261,324418K USD−87.0%

What has been filed or recorded for Allogene Therapeutics (ALLO)?

The filings we hold for Allogene Therapeutics, newest first: 6 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 29 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Allogene Therapeutics (ALLO)?
And
29 Oct 2026Fails to deliverShares failed to deliver875,974 shares1.1M USD notional · 0.253% of shares out
28 Oct 2026Fails to deliverShares failed to deliver189,481 shares233K USD notional · 0.055% of shares out
27 Oct 2026Fails to deliverShares failed to deliver666,195 shares806K USD notional · 0.192% of shares out
26 Oct 2026Fails to deliverShares failed to deliver9,223 shares12K USD notional · 0.003% of shares out
19 Oct 2026Fails to deliverShares failed to deliver1 shares1 USD notional · <0.001% of shares out
08 Oct 2026Fails to deliverShares failed to deliver18,512 shares26K USD notional · 0.005% of shares out
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS −0.15 USD
30 Sep 2026FinancialsTotal assets511.3M USDat period end
30 Sep 2026FinancialsTotal equity392.6M USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −0.13 USDRevenue $5M
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −0.18 USD
31 Dec 2025Annual reportFY 2025 reportedEPS −0.87 USD
31 Dec 2025FinancialsRevenue0 USDfiscal year
31 Dec 2025FinancialsNet income−190.9M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−0.87 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −0.19 USD
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −0.23 USD
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −0.28 USD
31 Dec 2024Annual reportFY 2024 reportedEPS −1.32 USDRevenue $0M

What do people ask about Allogene Therapeutics (ALLO)?

From live data
What did Allogene Therapeutics shares close at?0.6242

Allogene Therapeutics closed at 0.6242 USD on 20 Nov 2026, down 5.75% on the close before. That is the end-of-day price from Finazon, not a live quote.

What is Allogene Therapeutics’ market cap?216.2M

Allogene Therapeutics is worth 216.2M USD by market value as of 20 Nov 2026, which is the share price times the shares on issue from its SEC filings.

What is Allogene Therapeutics’ revenue?0

Allogene Therapeutics reported revenue of 0 USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

Have Allogene Therapeutics insiders bought or sold shares recently?1 sale

In the 90 days to 22 Nov 2026, Allogene Therapeutics insiders reported 1 open-market sale and no purchases (SEC Form 4); the filings we hold, back to 21 Oct 2025, show no open-market purchase. See Insiders

Which funds own Allogene Therapeutics?9 of 45

9 of the 45 funds we track reported a Allogene Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Citadel Advisors, Two Sigma Investments and Marshall Wace. See Funds

When did Allogene Therapeutics last report earnings?−0.15

Allogene Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.15 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  7. SEC EDGARreported earnings figures and scheduled report dates
  8. SEC EDGARValuation computed from SEC EDGAR filings
  9. SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words